Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension (NCT01785472), a randomized phase 3 study. The primary outcome is Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg.

2. Clinical Question

3. Trial Design

This was a Phase 3, randomized, double-blind, parallel-group, active-controlled study. The registry record lists enrollment of 1438 and describes a multicenter study lasting 8 weeks. The study was marked completed. Its recorded start was 2013-04, and primary completion was 2014-08. The sponsor was Novartis Pharmaceuticals.

The treatment arms included LCZ696 200 mg, LCZ696 400 mg, and olmesartan 20 mg. The 200 mg LCZ696 regimen was once daily throughout the 8 weeks. The 400 mg regimen began at 200 mg once daily for one week, followed by 400 mg once daily for the remaining seven weeks. Olmesartan was given at 20 mg once daily for 8 weeks. Placebos were listed in the treatment descriptions, consistent with the record’s double-blind designation.

The primary endpoint was change in mean sitting systolic blood pressure from baseline to 8 weeks, comparing LCZ696 200 mg with olmesartan 20 mg. The primary endpoint description says sitting blood pressure was measured at study visits, with four separate measurements and a full two-minute interval between measurements. The registry record says that the primary analysis included participants with baseline and week 8 values. It separately describes the FAS as randomized participants who received study medication and had post-baseline blood pressure assessments.

The original sample-size justification, allocation ratio, detailed visit schedule, and full protocol are not reported in the registry record. The record also does not report the intended handling of missing outcome values beyond defining the analysis population. These gaps limit how fully the prespecified design and analysis choices can be reconstructed from the registry entry alone.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Full Analysis Set (FAS): All patients who were randomized. Patients were analyzed according to the treatment they were assigned to at the randomization. However, patients who were not qualified for randomization and were inadvertently randomized into the study were excluded from the FAS, provided these patients did not receive study drug

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg, measured over baseline, 8 weeks.

The primary endpoint measures the change in mean sitting systolic blood pressure (msSBP), in mmHg, between baseline and 8 weeks. Systolic blood pressure is the pressure recorded during a heartbeat; the endpoint is specifically based on measurements taken while participants were sitting. The result is a group-level average change, rather than a count of participants reaching a threshold or an estimate of an individual response.

The registry describes four separate sitting blood pressure measurements at each assessment, with a full two-minute interval between measurements. Repeated readings can help represent a participant’s blood pressure at a visit more reliably than relying on one measurement. The endpoint compares changes from baseline, so it focuses on how the group averages shifted over the study period rather than simply comparing end-of-study readings.

The primary comparison was between LCZ696 200 mg and olmesartan 20 mg. The registry lists baseline and 8 weeks as the timeframe and reports the outcome as a least-squares mean. Least-squares means are model-based group averages; in this study, the reported analysis used ANCOVA. The registry record does not provide further details about the covariates or model specification.

This endpoint provides a defined short-term measure for comparing the two treatment groups in the trial. It does not, on its own, establish what happened beyond 8 weeks, characterize every participant’s experience, or answer questions about outcomes that were not part of this blood pressure measure.

7. Results Posted in the Registry

• Olmesartan 20 mg: mean -18.15 versus -20.48 on control; difference 2.33 (95% CI 0.64 to 4.02), standardized effect d = 0.17; z-test p = 0.007.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • Olmesartan 20 mg: mean -18.15 versus -21.67 on control; difference 3.52 (95% CI 1.82 to 5.22), standardized effect d = 0.26; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for Olmesartan 20 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • LCZ696 400 mg: mean -8.80 versus -8.10 on control; difference -0.70 (95% CI -1.74 to 0.34), standardized effect d = -0.09; z-test p = 0.187.
  • Olmesartan 20 mg: mean -6.86 versus -8.10 on control; difference 1.24 (95% CI 0.21 to 2.27), standardized effect d = 0.15; z-test p = 0.018.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between LCZ696 400 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for Olmesartan 20 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change From Baseline in Office Pulse Pressure (msPP)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • LCZ696 400 mg: mean -12.93 versus -12.35 on control; difference -0.58 (95% CI -1.76 to 0.60), standardized effect d = -0.06; z-test p = 0.335.
  • Olmesartan 20 mg: mean -11.25 versus -12.35 on control; difference 1.10 (95% CI -0.06 to 2.26), standardized effect d = 0.12; z-test p = 0.064.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between LCZ696 400 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Olmesartan 20 mg and the control. The interval gives the range of effects that remain compatible with the data.

The registry lists a broad set of secondary blood pressure outcomes, including sitting systolic and diastolic pressure, office pulse pressure, ambulatory blood pressure, and subgroup analyses by dipping status. The numerical summaries include additional sitting systolic pressure, diastolic pressure, and office pulse pressure comparisons. Their overall pattern is that the group averages generally decrease from baseline, while the size and precision of the between-group contrasts vary by outcome and dose.

These secondary measures extend the primary question to a different LCZ696 dose or to related blood pressure measures. They can provide context for whether the primary pattern is accompanied by changes in other measurements, but they are not interchangeable with the primary endpoint. Measures taken in an ambulatory setting and subgroup results address different aspects of blood pressure; no result for an outcome that is only listed, but lacks a numerical result in the record, should be inferred from the primary comparison.

The primary result remains the prespecified focus identified in the registry record. Secondary outcomes generally carry less weight when their testing plan and multiplicity adjustments are not documented. When many outcomes are examined, some apparently noteworthy results can arise by chance even if there is no corresponding underlying difference. The registry record does not report whether or how the secondary tests were adjusted for multiple comparisons.

Accordingly, secondary findings are best read as supportive or exploratory context, with attention to their estimates and uncertainty rather than isolated p-values. The record does not provide enough detail to establish a complete hierarchy of secondary hypotheses or to determine how their results were intended to influence the primary conclusion.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg
• Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg
• Change From Baseline in Office Pulse Pressure (msPP)
• Change From Baseline in Mean 24-hour Ambulatory Blood Pressure
• Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.
• Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.
• Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.
• Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.

9. Statistical Interpretation

10. Statistical Methods Explained

The primary endpoint is continuous: it is a measured quantity expressed in mmHg, summarized by group means. The registry identifies the primary measure as a least-squares mean with standard error as the dispersion measure. It reports ANCOVA for the comparison. The registry record does not report the full statistical analysis plan, the model covariates, or the detailed assumptions used for that analysis.

What does ANCOVA contribute?

In general, analysis of covariance compares groups while accounting for one or more variables included in the model. For a change-from-baseline endpoint, the model can incorporate baseline measurements or other prespecified covariates, depending on the analysis plan. This can make the reported adjusted contrast different from a simple subtraction of the displayed group means. The registry gives the method name but does not report enough model detail to determine exactly which covariates were included or how they were handled.

The registry-reported outcome is a least-squares mean, which is a model-based average, rather than necessarily the raw arithmetic average of each group’s observed changes. The associated net difference is the model’s contrast between groups. The sponsor’s analysis reports this contrast as -2.33 mmHg, with a 95% confidence interval and p-value. The sign depends on the order in which the contrast is expressed. The unadjusted recalculation uses olmesartan minus LCZ696 and therefore has the opposite sign.

What is the unadjusted recalculation?

The recalculated comparison uses the posted group summary estimates and their standard errors to form a simple between-group contrast. It is described as unadjusted because it does not reproduce the ANCOVA model. The comparison is useful as a transparent check on the direction and approximate size of the contrast, but it lacks the model-based adjustments described for the sponsor analysis. It should not be read as an alternative prespecified primary analysis.

The recalculation also uses an approximate pooled standard deviation for the primary comparison. That is a derived descriptive quantity rather than a directly reported outcome measure. Its use does not alter the posted group means or turn the recalculation into the registry’s ANCOVA. The registry’s own analysis remains the reported model-based result; the record does not identify a discrepancy between the recalculation and sponsor result.

What does the standard error tell readers?

In general, a standard error describes the statistical uncertainty in an estimated average. It is not the same as the spread of individual participants’ measurements. A relatively small standard error can occur when an average is estimated precisely, even when individuals vary considerably. The primary group estimates have a reported standard error of 0.61 mmHg in each arm. The registry does not give the individual-level distribution of blood pressure changes in this entry.

For continuous outcomes, differences in group averages are often presented with confidence intervals. A confidence interval describes a range of values compatible with the data and the statistical method under its assumptions. It is not a range that contains a specified fraction of individual responses. The reported interval belongs to the ANCOVA analysis; the recalculated interval belongs to the simple unadjusted contrast. Their methods and contrast direction need to be kept clear when comparing them.

Why can over-dispersion matter?

In general, over-dispersion means that observed variation is greater than a statistical model expects. It is especially relevant to count outcomes, where assuming too little variation can make uncertainty estimates too narrow. The primary outcome is continuous, and the registry reports standard errors rather than a count model. Over-dispersion is therefore not the central issue for interpreting this primary endpoint. The registry record does not report a special over-dispersion adjustment for the blood pressure analysis.

How should p-values be understood?

In general, a p-value describes how compatible observed data are with a specified null model, given the analysis assumptions. It does not measure the size or importance of an effect, and it is not the probability that the null hypothesis is true. The sponsor-reported p-value is from the ANCOVA analysis; the recalculated p-value is unadjusted and arises from a different calculation. The registry record does not report a complete account of the testing hierarchy or multiplicity procedures.

The reported-analysis classification is non-inferiority or equivalence, but the record does not state the margin used or give the full decision framework. Without those details, the classification alone does not allow readers to reconstruct the formal criterion. Likewise, the registry record does not report interim analyses or other planned adaptations.

What analysis population is described?

The primary analysis description states that only participants with both baseline and week 8 values were included. The record also defines the FAS as all randomized participants who received study medication and had post-baseline blood pressure assessments. These statements describe the population criteria, but do not establish how many participants were excluded from the primary analysis or why. A missing-data method beyond the stated inclusion criterion is not reported in the registry record.

These distinctions matter because the model, analysis population, missing-data approach, and testing plan all shape the interpretation of a treatment contrast. The registry entry documents the principal endpoint and the sponsor’s method name, but not every detail required to reproduce or audit the full analysis.

11. Confidence Intervals and Precision

The sponsor-reported primary estimate is -2.33 mmHg, with a 95% confidence interval from -4.00 to -0.66. The interval gives a sense of the estimate’s precision under the reported ANCOVA method: it spans values on the same side of zero as the reported contrast. Its width reflects uncertainty in the estimated group difference, not the range of changes expected for individual participants. The sponsor-reported p-value is p < 0.001.

The unadjusted recalculation reports a difference of 2.33 mmHg, with a 95% confidence interval from 0.639 to 4.021 and p = 0.007. The recalculated contrast is expressed in the opposite direction from the sponsor’s ANCOVA contrast. The two intervals are associated with different methods, so their endpoints should not be compared as though they were produced by one identical model.

In general, a confidence interval represents uncertainty around an estimate under the assumptions of the analysis. It is not a guarantee that the true value lies within the interval, and it does not describe the distribution of participant-level outcomes. Precision is also distinct from clinical importance: judging importance would require context not established by the statistical interval alone.

The standard errors reported for the primary group means are 0.61 mmHg for both arms. The registry record does not give the full model specification, covariates, or individual data needed to independently reproduce the sponsor’s interval. The model-based interval is therefore best understood as the result reported by the registry, while the recalculated interval is a separate unadjusted estimate based on posted summaries.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning illustrations are for participants per arm, not total events. They use the stated observed effect or a stated fraction of it, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The trial’s own original design assumptions and sample-size justification are not reported in the registry record; these planning illustrations are not a reconstruction of those original choices.

For the primary comparison, planning for 100% of the observed effect gives 515 participants per arm for 80% power and 689 participants per arm for 90% power. Planning for 75% of the observed effect gives 915 participants per arm for 80% power and 1,224 participants per arm for 90% power. Planning for 50% of the observed effect gives 2,058 participants per arm for 80% power and 2,754 participants per arm for 90% power.

In general, 80% power means that a design with the stated assumptions would have an 80% chance of detecting the specified effect at the chosen significance level if that effect were the true one. The 90% power column uses the same idea with a higher chance of detection. Smaller target effects generally require more participants to detect reliably, which is why the planning counts rise as the target fraction of the observed effect falls.

These are planning illustrations, not observed power. They depend on the assumptions stated above and should not be interpreted as evidence about the trial’s actual design process or as a measure of how successful its completed analysis was.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 2.330; pooled standard deviation σ = 13.337.
2. n = 2 × (1.96 + 0.842)² × 13.337² / 2.330² = 514.3, rounded up to 515 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 2.33                      # observed difference in means
sigma <- 13.3365880225737                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(1785472)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 515 (80% power), 689 (90% power)
 75% of observed effect: n per arm = 915 (80% power), 1,224 (90% power)
 50% of observed effect: n per arm = 2,058 (80% power), 2,754 (90% power)
power.t.test: 515.3 
Simulated power at n = 515 per arm: 0.801 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports the sponsor’s primary analysis as ANCOVA, with a least-squares-means net difference of -2.33 mmHg, a 95% confidence interval from -4.00 to -0.66, and p < 0.001. The unadjusted recalculation from posted summary statistics expresses the contrast in the reverse direction: olmesartan minus LCZ696 is 2.33 mmHg, with a 95% confidence interval from 0.639 to 4.021 and p = 0.007. The estimates have opposite signs because the contrast order differs.

The recalculation is a simple unadjusted comparison and does not replicate the sponsor’s ANCOVA. Model adjustment, including any covariates used, can affect the estimate and its uncertainty; the registry record does not give the model specification needed to reproduce that analysis. The registry record does not flag a discrepancy. The sponsor’s reported analysis is therefore the appropriate result to identify as the registry’s primary analysis, while the recalculation is a separate descriptive check based on posted summaries.

The record classifies the sponsor analysis as non-inferiority or equivalence. The margin and complete decision criteria are not reported in the registry record, so the estimate and interval alone do not provide enough information to reconstruct that formal framework.

15. Multiplicity, Missing Data and Analysis Populations

The registry identifies one primary outcome and reports one sponsor analysis for the primary comparison. It also lists secondary outcomes covering several blood pressure measures and subgroups. Examining multiple outcomes creates a multiplicity issue: the more statistical comparisons made, the greater the chance that some results appear unusual by chance alone. In general, a prespecified testing hierarchy or adjustment procedure can help control that risk.

The registry record does not report whether secondary analyses were adjusted for multiplicity, what testing hierarchy was used, or whether particular secondary outcomes were intended to be confirmatory or exploratory. It also does not report interim analyses. These choices should not be guessed from the posted outcome list or from the p-values. Without the analysis plan, the strength of evidence for individual secondary findings is harder to assess.

The primary analysis population is described as participants with both baseline and week 8 values. The record also describes the FAS as randomized participants who received study medication and had post-baseline blood pressure assessments. It does not report the number of participants missing each measurement, reasons for missingness, or a sensitivity analysis addressing missing outcomes. A method for imputing or otherwise handling missing data beyond the stated population criteria is not reported in the registry record.

These omissions matter because complete-value analyses can be affected if participants with missing measurements differ systematically from those with observed values. The registry record does not establish whether missingness was related to treatment, blood pressure response, or other factors. Nor does it provide enough information to evaluate whether the stated analysis populations were prespecified in the same form as reported.

The original sample-size justification, detailed statistical analysis plan, covariate selection, and non-inferiority margin are also not reported in the registry record. Their absence limits assessment of how the analysis was planned, how multiplicity was managed, and how the sponsor’s formal classification was determined.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: gastroenteritis (0.2%), spinal osteoarthritis (0.2%), thyroid neoplasm (0.2%), bile duct stone (0.2%), cholelithiasis (0.2%).

The registry reports serious adverse events for three treatment groups. The listed counts were 5 among 478 at risk in the LCZ696 200 mg group, 3 among 472 at risk in the LCZ696 400 mg group, and 6 among 484 at risk in the olmesartan 20 mg group. These are reported event counts alongside the corresponding at-risk counts; they should not be converted into comparative rates without a specified analysis and denominator interpretation.

The registry also lists serious adverse event terms, each shown as 0.2%: gastroenteritis, spinal osteoarthritis, thyroid neoplasm, bile duct stone, cholelithiasis, and alanine aminotransferase increased. The entry does not provide enough detail in these fields to determine the full clinical course, event timing, or how individual events were attributed.

Deaths are not reported in the registry record. A missing death count should not be interpreted as evidence that no deaths occurred. Serious adverse event counts are descriptive safety information, not by themselves a complete comparison of risk or a basis for medical decisions. Follow-up was 8 weeks, and the registry record does not provide a longer-term safety assessment in these results.

17. What the Result Does, and Does Not, Mean

The posted primary data show that mean sitting systolic blood pressure declined from baseline in both the LCZ696 200 mg and olmesartan 20 mg groups over the 8-week timeframe. The registry’s ANCOVA analysis reports a between-group least-squares-means contrast, while the unadjusted recalculation gives a similar-sized contrast in the reverse direction. Each result describes an average comparison under its own method.

This does not show that every participant experienced the group-average change, or that all participants responded in the same way. Group means can conceal variation in individual outcomes. The registry entry does not report the distribution of individual changes or the proportion of participants with particular responses.

The study’s primary endpoint is a short-term blood pressure measure. It does not, by itself, establish effects on cardiovascular events, quality of life, or outcomes beyond the study follow-up. Those outcomes cannot be inferred from a change in sitting blood pressure alone. The record also does not provide a basis for extending the results to populations other than the Asian patients with essential hypertension described in the trial.

The registry classifies the primary analysis as non-inferiority or equivalence, but it does not report the margin or the full decision criteria. Readers should therefore distinguish the reported classification from an independent reconstruction of the formal conclusion. The posted estimate, confidence interval, and p-value describe statistical evidence under the reported analysis; they do not settle questions of clinical importance or individual treatment choice.

Overall, the results are evidence about an average between-group change in a defined endpoint, population, and timeframe. They are not a complete account of benefits and harms, and they should be interpreted alongside the limited safety information and the analysis details not reported in the registry record.

18. Why This Trial Matters Statistically

This trial illustrates why the contrast definition matters. The sponsor’s ANCOVA estimate and the unadjusted recalculation have opposite signs because they express the group difference in opposite orders. Reading only the sign without identifying the contrast direction could lead to a mistaken description. The estimates should also be distinguished by method: one is model-based and reported by the registry; the other is an unadjusted calculation from summary statistics.

The trial also shows the difference between a group mean change and a treatment contrast. Both groups have negative mean changes, but the primary comparison asks how much those changes differ on average. Confidence intervals add information about precision that a point estimate alone cannot convey. They do not, however, describe the range of individual responses or establish clinical importance.

Other statistical issues are visible in the record. It specifies an analysis population based on observed baseline and week 8 values, while not giving a detailed missing-data method. It lists multiple secondary outcomes without documenting multiplicity procedures. It classifies the primary analysis as non-inferiority or equivalence without reporting the margin. Each omission constrains interpretation in a different way.

The planning illustrations also demonstrate that required sample size depends on the effect a future study aims to detect: smaller target effects require larger participant counts under the stated planning assumptions. Those illustrations are separate from the original design rationale, which is not reported in the registry record. Taken together, the study is a useful example of reading an endpoint, an adjusted analysis, an unadjusted recalculation, and uncertainty as related but distinct parts of a clinical trial result.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary result is limited to mean sitting systolic blood pressure change over 8 weeks. The registry record does not establish longer-term outcomes or report clinical event outcomes in this result set. Its population is described as Asian patients with essential hypertension, so broader generalization is not established by this entry alone.

The registry reports ANCOVA but does not give its full model specification, including the covariates used. That prevents independent reproduction of the sponsor’s adjusted estimate from the record. The non-inferiority or equivalence classification is also difficult to evaluate without the margin and detailed decision criteria, which are not reported in the registry record.

The primary analysis description requires both baseline and week 8 values. The record does not provide counts or reasons for missing measurements, a detailed missing-data procedure, or sensitivity analyses. It therefore does not allow readers to assess how missing outcomes may have affected the comparison. The FAS description is also stated separately, without a detailed account of how it relates to the primary analysis set.

The record lists numerous secondary measures, including subgroup and ambulatory blood pressure outcomes, but does not report a complete multiplicity strategy. This limits the interpretation of secondary p-values and the strength of any patterns across those outcomes. The entry also does not report interim analyses or the original sample-size justification. Finally, the safety information presented is limited to serious adverse event summaries and listed terms; deaths are not reported in the registry record, and these data do not provide a full assessment of safety over longer follow-up.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension — NCT01785472.
• Registry record last updated 2016-12-29; status last verified 2016-11.
• Results first posted 2015-09-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

The registry record describes a completed, randomized, double-blind, parallel-group, active-controlled Phase 3 study of LCZ696 and olmesartan in Asian patients with essential hypertension. Enrollment was 1438, and the study timeframe was 8 weeks. The primary endpoint was change in mean sitting systolic blood pressure from baseline to 8 weeks, comparing LCZ696 200 mg with olmesartan 20 mg.

The sponsor-reported ANCOVA result was a least-squares-means net difference of -2.33 mmHg, with a 95% confidence interval from -4.00 to -0.66 and p < 0.001. The unadjusted recalculation expresses the contrast in the reverse direction and is distinct from that model-based analysis. Secondary blood pressure measures and serious adverse event summaries add context, while key details about multiplicity, missing-data handling, the non-inferiority margin, and the original design assumptions are not reported in the registry record.